オキシラセタム
オキシラセタム · 2-(4-ヒドロキシ-2-オキソ-1-ピロリジニル)アセトアミド · 2-(4-ヒドロキシ-2-オキソピロリジン-1-イル)アセトアミド · 4-ヒドロキシ-2-オキソ-1-ピロリジンアセトアミド · オキシルアセタム · ヒドロキシピラセタム · 4-hydroxy-2-oxo-1-pyrrolidineacetamid · 2-(4-Hydroxy-2-oxopyrrolidin-1-yl)acetamide
識別子と物理属性
| CAS No. | 62613-82-5 |
|---|---|
| 分子式 | C6H10N2O3 |
| 平均分子量 | 158.16 g/mol |
| 単同位体質量 | 158.06914218 g/mol |
| SMILES | NC(=O)CN1CC(O)CC1=O |
| InChIKey | IHLAQQPQKRMGSS-UHFFFAOYSA-N |
| PubChem CID | 4626 |
| ChEMBL | CHEMBL36633 |
| ChEBI | CHEBI:134788 |
| EC No. | 636-370-0 |
| DTXSID | DTXSID9045180 |
| 現地名 | オキシラセタム |
化学・物理的性質
| XLogP | -2.2 |
|---|---|
| 極性表面積 | 83.6 |
| 水素結合供与体数 | 2 |
| 水素結合受容体数 | 3 |
| 回転可能結合数 | 2 |
| 重原子数 | 11 |
| 形式電荷 | 0 |
| 複雑度 | 192 |
| 医薬品 | DEA NFLIS-Drug Category -> Stimulants |
| 融点 | 165-168 °C |
| 沸点 | 494.6±40.0 °C(Predicted) |
| 密度 | 1.416 |
| 貯蔵条件 | Sealed in dry,Room Temperature |
| 溶解度 | DMSO（微加熱）、メタノール（微加熱） |
| 外観・状態 | 個体 |
| pKa（酸解離定数） | 13.76±0.20(Predicted) |
| 色 | ホワイトからオフホワイト |
| Merck | 14,6942 |
| InChI | InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10) |
| InChIKey | IHLAQQPQKRMGSS-UHFFFAOYSA-N |
| SMILES | N1(CC(N)=O)CC(O)CC1=O |
| CAS データベース | 62613-82-5(CAS DataBase Reference) |
化学的特性
Whie Solid
安全性と法規制
| GHS 分類 | WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P264, P264+P265, P280, P302+P352, P305+P351+P338, P321, P332+P317, P337+P317, and P362+P364 (click each P-code to see the statement)Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (100%) |
| 水環境危害等級（WGK） | 3 |
| RTECS 番号 | UX9656638 |
| 税関コード | 2933.79.8500 |
| 危険文句（R） | 36/38 |
| 危険表示 | Xi |
| 安全措置（S） | 26-36 |
| 貯蔵分類 | 11 - Combustible Solids |
用途
説明
Oxiracetam is a structural analogue of piracetam. This compound has enhancing effects on vigilance and memory. In comparison with piracetam, oxiracetam exhibits greater improvement in memory (Itil et al., 1986) and has been used extensively for the treatment of dementia, including AD, VaD, MID (Baumel et al., 1989; Dysken et al., 1989), and mixed forms. Green et al. (1992) failed to demonstrate a difference from placebo in AD patients. In contrast, Maina et al. (1989) studied 289 patients with MID in a double-blind placebo-controlled trial and after 12 weeks of treatment found that oxiracetam reduced behavioural symptoms.
使用
Oxiracetam is a 4-hydroxy analog of piracetam with psychostimulant activity, reportedly useful in relieving the symptoms of cerebral insufficiency in the elderly.
製法・合成法
純化方法
This nootropic (Alzheimer) drug is purified by recrystallisation from MeOH or aqueous Me2CO and dried in vacuo. [NMR, IR: Pifferi & Pinza Farmaco Ed Sci 32 602 1977, Banfi et al. Farmaco Ed Sci 39 16 1984, Gouilaev & Senning Brain Research Rev 19 180 1994.]